LifeMD Inc (NASDAQ: LFMD) closed the day trading at $10.87 up 0.28% from the previous closing price of $10.84. In other words, the price has increased by $+0.03 from its previous closing price. On the day, 1102713 shares were traded.
Ratios:
For a better understanding of LFMD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 50.91. For the most recent quarter (mrq), Quick Ratio is recorded 1.15 and its Current Ratio is at 1.22. In the meantime, Its Debt-to-Equity ratio is 5.39 whereas as Long-Term Debt/Eq ratio is at 5.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on November 30, 2023, initiated with a Buy rating and assigned the stock a target price of $10.
On July 21, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $7.
On July 03, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $9.H.C. Wainwright initiated its Buy rating on July 03, 2023, with a $9 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 31 ’23 when Velge Bertrand bought 60,000 shares for $3.93 per share. The transaction valued at 235,800 led to the insider holds 349,482 shares of the business.
Velge Bertrand bought 40,000 shares of LFMD for $150,400 on Aug 30 ’23. The Director now owns 289,482 shares after completing the transaction at $3.76 per share. On Aug 29 ’23, another insider, Velge Bertrand, who serves as the Director of the company, bought 32,072 shares for $3.58 each. As a result, the insider paid 114,818 and bolstered with 249,482 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LFMD now has a Market Capitalization of 436.05M and an Enterprise Value of 421.83M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.88 while its Price-to-Book (P/B) ratio in mrq is 118.63. Its current Enterprise Value per Revenue stands at 2.77 whereas that against EBITDA is -53.47.
Stock Price History:
The Beta on a monthly basis for LFMD is 1.42, which has changed by 676.43% over the last 52 weeks, in comparison to a change of 31.54% over the same period for the S&P500. Over the past 52 weeks, LFMD has reached a high of $11.06, while it has fallen to a 52-week low of $1.14. The 50-Day Moving Average of the stock is 6.96, while the 200-Day Moving Average is calculated to be 5.82.
Shares Statistics:
Over the past 3-months, LFMD traded about 910.08K shares per day on average, while over the past 10 days, LFMD traded about 1.25M shares per day. A total of 38.26M shares are outstanding, with a floating share count of 31.21M. Insiders hold about 22.69% of the company’s shares, while institutions hold 30.92% stake in the company. Shares short for LFMD as of Feb 29, 2024 were 2.73M with a Short Ratio of 3.00, compared to 2.46M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.97% and a Short% of Float of 8.26%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of -$0.09 and a low estimate of -$0.18, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.13 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.37 and -$0.59 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.22, with 3 analysts recommending between -$0.1 and -$0.31.
Revenue Estimates
4 analysts predict $42.48M in revenue for the current quarter. It ranges from a high estimate of $42.81M to a low estimate of $42M. As of the current estimate, LifeMD Inc’s year-ago sales were $30.8M, an estimated increase of 37.90% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $47.4M, an increase of 31.90% less than the figure of $37.90% in the same quarter last year. There is a high estimate of $48.5M for the next quarter, whereas the lowest estimate is $46.28M.
A total of 4 analysts have provided revenue estimates for LFMD’s current fiscal year. The highest revenue estimate was $204.5M, while the lowest revenue estimate was $200.02M, resulting in an average revenue estimate of $201.65M. In the same quarter a year ago, actual revenue was $152.55M, up 32.20% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $245.07M in the next fiscal year. The high estimate is $258.39M and the low estimate is $235.81M. The average revenue growth estimate for next year is up 21.50% from the average revenue estimate for this year.
